Effects of vedolizumab on health‐related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial

por Feagan, B. G., Patel, H., Colombel, J.‐F., Rubin, D. T., James, A., Mody, R., Lasch, K.
Publicado 2016

Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease

por Vande Casteele, N., Feagan, B. G., Vermeire, S., Yassine, M., Coarse, J., Kosutic, G., Sandborn, W. J.
Publicado 2017

A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-...

por Sands, B E, Feagan, B, Gibble, T H, Traxler, K A, Morris, N, Li, X, Schreiber, S, Jairath, V, Armuzzi, A, Jones, J
Publicado 2023

A42 HETEROGENEITY IN EFFICACY AND SAFETY ENDPOINTS FOR PEDIATRIC CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE: A NEED FOR HARMONIZATION

por Crowley, E, Turner, D, Ma, C, Nguyen, T, McKay, H, Schneider, R, Silverberg, A, Muise, A, Feagan, B, Griffiths, A, Jairath, V
Publicado 2022

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

por Rosario, M., Dirks, N. L., Gastonguay, M. R., Fasanmade, A. A., Wyant, T., Parikh, A., Sandborn, W. J., Feagan, B. G., Reinisch, W., Fox, I.
Publicado 2015

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventiona...

por Colombel, J.‐F., Jharap, B., Sandborn, W. J., Feagan, B., Peyrin‐Biroulet, L., Eichner, S. F., Robinson, A. M., Mostafa, N. M., Zhou, Q., Thakkar, R. B.
Publicado 2016

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

por Sandborn, W. J., Rutgeerts, P., Gasink, C., Jacobstein, D., Zou, B., Johanns, J., Sands, B. E., Hanauer, S. B., Targan, S., Ghosh, S., de Villiers, W. J. S., Colombel, J.‐F., Feagan, B. G.
Publicado 2018

Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis

por Rutgeerts, P., Feagan, B. G., Marano, C. W., Padgett, L., Strauss, R., Johanns, J., Adedokun, O. J., Guzzo, C., Zhang, H., Colombel, J.‐F., Reinisch, W., Gibson, P. R., Sandborn, W. J.
Publicado 2015

A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

por Panaccione, R, Ferrante, M, Feagan, B G, Sandborn, W, Panes, J, Peyrin-Biroulet, L, Colombel, J, Schreiber, S, Dubinsky, M, Baert, F, Hisamatsu, T, Neimark, E, Huang, B, Liao, X, Song, A, Berg, S, Duan, W, Pang, Y, Pivorunas, V, Kligys, K, Wallace, K, D’Haens, G
Publicado 2022

Randomised clinical trial: a phase 1, dose‐ranging study of the anti‐matrix metalloproteinase‐9 monoclonal antibody GS‐5745 versus placebo for ulcerative colitis

por Sandborn, W. J., Bhandari, B. R., Fogel, R., Onken, J., Yen, E., Zhao, X., Jiang, Z., Ge, D., Xin, Y., Ye, Z., French, D., Silverman, J. A., Kanwar, B., Subramanian, G. M., McHutchison, J. G., Lee, S. D., Shackelton, L. M., Pai, R. K., Levesque, B. G., Feagan, B. G.
Publicado 2016

A236 ASSOCIATION OF STOOL METABOLOMIC PROFILE AND MICROBIOME COMPOSITION RISK SCORE WITH FUTURE ONSET OF CROHN’S DISEASE

por Lee, S, Raygoza Garay, J, Turpin, W, Smith, M I, Goethel, A, Griffiths, A, Moayyedi, P, Espin-Garcia, O, Aumais, G, Bernstein, C N, Avni-Biron, I, Cino, M, Deslandres, C, Dotan, I, El-Matary, W, Feagan, B G, Guttmen, D S, Huynh, H Q, Hyams, J, Jacobson, K, Mack, D R, Marshall, J, Otley, A, Panaccione, R, Silverberg, M S, Steinhart, H, Turner, D, Xu, W, Croitoru, K
Publicado 2022